[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634003":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":43,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Zhujiang Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Probiotics combined with neoadjuvant chemoimmunotherapy","EXPERIMENTAL",null,[13],"Drug: Probiotics combined with neoadjuvant chemoimmunotherapy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","This clinical study aims to enhance efficacy by using functional probiotics selected from a Chinese food-grade probiotic library in combination with neoadjuvant chemoimmunotherapy.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Xin Li","CONTACT","+8619878478083","1098353704@qq.com",[26],{"facility":27,"status":28,"city":29,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Zhu Jiang Hospital of Southern Medical University","RECRUITING","Guangzhou","China","CN",{"type":33,"coordinates":34},"Point",[35,36],113.25,23.11667,{"lat":36,"lon":35},[39],{"name":40,"role":22,"phone":41,"phoneExt":11,"email":42},"Xiaolong He","18620071640","hxl2027315@smu.edu.cn",{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100634003","phase-2-phase-ii-clinical-study-of-probiotic-lr607-in-patients-with-non-small-cell-lung-cancer-100634003",false,"NCT07534033","Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer","Probiotics With High Expression of DL-peptidase (LR607) Can Enhance the Efficacy of Chemoradiotherapy in Resectable Stage IIB-IIIB Non-small Cell Lung Cancer: a Single-arm, Open-label, Multicenter, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Histologically confirmed newly diagnosed patients\n2. ECOG performance status 0-1\n3. Age ≥18 years\n4. Measurable lesions (RECIST v1.1)\n5. Organ function meeting the requirements for chemotherapy and immunotherapy.\n\nExclusion Criteria:\n\n1. Including active autoimmune diseases\n2. Recent use of immunosuppressants\n3. Interstitial lung disease\n4. Presence of other malignancies\n5. History of immunotherapy\n6. Active infection\n7. Pregnancy or drug allergies",true,"ALL","18 Years","80 Years",{"count":57,"type":58},46,"ESTIMATED","INTERVENTIONAL",[61],"PHASE2","The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include:\n\nCan LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combined with neoadjuvant chemoimmunotherapy and treatment-related adverse reactions? What changes occur in the gut microbiota composition at the species level and gut metabolites of subjects after LR607 treatment?\n\nParticipants will:\n\nTake LR607 daily for 3 months Visit the hospital for check-ups and examinations every month Record their pathological response, tumor recurrence, and treatment-related adverse reactions",[64,65,66,67],"NSCLC Diagnosed by Histology or Cytology","A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection","Overall Lung Function is Adequate for the Planned Lung Resection","AJCC is Classified as IB-IIIC",[69,70,71],"NSCLC","IB-IIIC stage","Resectable NSCLC","2026-04-13",{"date":74,"type":75},"2026-04-16","ACTUAL",{"date":77,"type":75},"2025-12-06",{"date":79,"type":58},"2027-12-23",{"name":5,"class":6},1]